drugset / Trial / NCT01624571
Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This clinical trial is conducted to determine the optimal dose of LD02GIFRO in improvement of gastrointestinal motility between each dose group by comparing the effectiveness and safety in patients undergoing colon resection.
Timeline
- Start
- 2012-03
- Primary completion
- 2012-10
- Completion
- 2012-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LD02GIFRO | Unknown | 300 mg | — |
| Subject | LD02GIFRO | Unknown | 600 mg | — |
| Subject | LD02GIFRO | Unknown | 900 mg | — |
Indications
No indication recorded.